QUOTE AND NEWS
Mondo Visione  Feb 18  Comment 
Audit Oversight Board (AOB) has publicly reprimanded two registered  auditors, Lim Kok Beng of Ong Boon Bah & Co and Chan Kee Hwa of Khoo Wong & Chan for failing to comply with the International Standards on Auditing (ISAs) while auditing the...
Mondo Visione  Aug 28  Comment 
The Audit Oversight Board (AOB) today reprimanded two auditors for failing to discharge their professional duties as set out in the International Standards on Auditing (ISA). One of the auditors was also fined RM10,000 for breaching the ISA and...
Mondo Visione  Aug 19  Comment 
The Audit Oversight Board (AOB) today reprimanded four auditors for failing to discharge their professional duties as set out in the International Standards on Auditing. On top of that, one of the auditors was also fined RM5,000 for breaching the...
Mondo Visione  Dec 19  Comment 
Auditors and audit firms need to do more to improve their consistency of performance, noted by the first global survey on audit regulators’ inspection findings released by the International Forum of Independent Audit Regulators (IFIAR)...
Mondo Visione  Oct 5  Comment 
Financial Services Agency (FSA) and Certified Public Accountants and Auditing Oversight Board (CPAAOB) exchanged the Letters on cooperation in the area of audit oversight with the Audit Oversight Board (AOB) of Malaysia on October 3, 2012. In...
Mondo Visione  Oct 4  Comment 
The Audit Oversight Board Malaysia (AOB) today established official collaboration in audit oversight with the Japan Financial Services Authority (JFSA) and the Certified Public Accountants Audit Oversight Board (CPAAOB). The collaboration was...
Globe Newswire  Jul 13  Comment 
NEW YORK, July 13, 2012 (GLOBE NEWSWIRE) -- Shareholders of American Oriental Bioengineering, Inc. ("AOBI" or the "Company") (OTC:AOBI) are reminded of the federal securities class action filed against AOBI and certain of its officers. The securities
Globe Newswire  Jul 5  Comment 
NEW YORK, July 5, 2012 (GLOBE NEWSWIRE) -- Pomerantz Haudek Grossman & Gross LLP has filed a federal securities class action 12-cv-05789-JAK-RZx in United States District Court, Central District of California, on behalf of all persons who purchased
Globe Newswire  Jul 4  Comment 
NEW YORK, July 3, 2012 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. reminds investors of the important August 22, 2012 lead plaintiff deadline in the class action the Rosen Law Firm filed on behalf of investors who purchased the common stock of
Benzinga  May 31  Comment 
American Oriental Bioengineering, Inc. (NYSE: AOB) today announced that it received written notification on May 25, 2012, from the NYSE Regulation, Inc. staff, on behalf of the New York Stock Exchange LLC ("NYSE"), that the staff had determined to...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

American Oriental Bioengineering Inc. (AOB), together with its wholly owned subsidiaries, is a pharmaceutical company which develops, manufactures and commercializes both plant-based pharmaceutical (PBP) and plant-based nutraceutical (PBN) products.

PBPs are Traditional Chinese Medicine (TCM) based on non-synthetic medicinal compounds that are extracted from leaves and roots of one or more plants. Each PBP has certain medicinal functions and proven efficacy in the treatment of at least one or more illnesses or symptoms of illnesses. The company's PBP products are approved by the Chinese State Food and Drug Administration (SFDA) and are being sold both as prescriptions and over-the-counter (OTC) medicine. PBNs, also frequently referred to as "dietary supplements" or "nutritional supplements", are prophylactic or preventive, in contrast to PBP products which are used to treat an illness or symptoms of an illness. PBNs represent a different approach to medicine as they are supplementary to nutrition taken from a normal diet and help improve health or wellness of the whole body. The PBN products are approved by local government agencies to be labeled as nutraceutical products.

AOB currently offers over 20 PBP and PBN products in China. Core PBP products include Shuanghuanlian Lyophilized Injection Powder, a leading anti-viral injection effective in treating respiratory diseases, Cease Enuresis Soft Gel and Patch, a prescription medicine specially formulated to help alleviate bed-wetting and incontinence and other over-the-counter drugs, such as Jinji Capsule to treat gynecological inflammations and pre-menstrual symptoms. Core PBN products include a line of health supplements including soybean peptide products and nutritional beverages. All of the company's core products enjoy branded market leadership in China in the segments in which they compete. Because of the significance of these brands to the business, AOB concentrates its sales and marketing efforts in promoting them in target markets.

Key product sales as percentage of total revenue










2004


2005


2006


Plant-based Pharmaceutical (PBP products)







    Shuanghuanglian lyophilized injection powder 

16%


30%


25%


    Cease-enuresis soft gel and patch  

21%


22%


23%


    Jinji Capsule               

-


-


19%









Plant-based Nutraceutical (PBN products)







    Soy peptide series             

36%


28%


25%









The company finished its reverse takeover in 2003 and its shares were listed in OTCBB since then until July 2005 when the company's shares were listed in American Stock Exchange. In December 2006, the company's common stock commenced trading on New York Stock Exchange under the ticker of AOB. Headquartered in Harbin, China, AOB employs about 1981 employees.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki